TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...
While brand-name weight loss drugs are in short supply, a market for alternatives thrives
High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...
New migraine drugs no better than cheap painkillers: big study
New, more expensive migraine drugs are no more effective against the throbbing headaches than traditional painkillers, and ...
An appeals court has revived a challenge to President Biden's Medicare drug price reduction program
A constitutional challenge to the Biden administration program enabling Medicare to negotiate lower prices for prescription ...
STAT1d
Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
Challenge to US drug price negotiation program revived by appeals court
A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the first-ever U.S. law ...
Spotlight on AbbVie: Analyzing the Surge in Options Activity
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...
Novo Nordisk Shares Drop Nearly 5% on Disappointing Obesity Pill Data
LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish ...
India Today on MSN2d
New drugs for migraines as effective as cheap painkillers
A new global study has found that expensive migraine medications that are newer than older painkillers are no more effective ...
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.
JD Supra4d
Ubrelvy Untitled Letter – A Double Fault for AbbVie? Or Makeup Misread for FDA?
The next frame shows the Ubrelvy logo in the backstage hallway along with a blue lit path. Frames six to seven then show Serena Williams walking down the blue lit path, no longer exhibiting migraine ...